CORRECT: Omeros Gets FDA Ok for Yartemlea in TA-TMA

(Corrects to clarify the approval was reported on Dec. 24.)

Omeros gets FDA approval of Yartemlea injection to treat adults and children 2 years and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy as the first approved treatment option.

• Yartemlea received priority review, breakthrough therapy designation and orphan drug designation for this indication
• NOTE: Dec. 24, Omeros Gets FDA Approval for Yartemlea in TA-TMA

To view the source of this information, click here

To contact the reporter on this story:
Lin Cheng in New York at lcheng97@bloomberg.net

To contact the editor responsible for this story:
Ilya Banares at ibanares@bloomberg.net

© ...